3.46
+0.09(+2.67%)
Currency In USD
Address
103 Carnegie Center
Princeton, NJ 08540
United States of America
Phone
818 839 4378
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
February 07, 2012
| Name | Title | Pay | Year Born |
| Prashant Kohli | Chief Executive Officer & Director | 750,000 | 1972 |
| Amresh Kumar | VP of Program Management | 371,800 | 1980 |
| Carrie D'Andrea | VP of Clinical Operations | 371,800 | 1972 |
| R. Loch MacDonald | Member of Scientific Advisory Board & Chief Medical Officer | 0 | 1962 |
| Robert J. DelAversano | Vice President of Finance and Principal Financial & Accounting Officer | 0 | 1972 |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
